AIMS: CIC-rearranged sarcomas (CRS) are clinically aggressive undifferentiated round cell sarcomas (URCS), commonly driven by CIC::DUX4. Due to the repetitive nature of DUX4 and the variability of the fusion breakpoints, CIC::DUX4 fusion may be missed by molecular testing. Immunohistochemical (IHC) stains have been studied as surrogates for the CIC::DUX4 fusion. We aim to assess the performance of DUX4 IHC in the work-up of CRS and its expression in non-CRS round cell or epithelioid neoplasms. METHODS AND RESULTS: Cases of molecularly confirmed CRS (n = 48) and non-CRS (n = 105) were included. CRS cases consisted of 35 females and 13 males, with ages ranging from less than 1 year to 67 years (median = 41 years). Among the molecularly confirmed non-CRS cases, C-terminal DUX4 expression was investigated in Ewing sarcomas (38 cases), alveolar rhabdomyosarcomas (18 cases), desmoplastic small round cell tumours (12 cases) and synovial sarcomas (n = five), as well as in non-mesenchymal neoplasms such as SMARCA4/SMARCB1-deficient tumours (n = five), carcinomas of unknown primary (n = three) and haematolymphoid neoplasms (four cases). DUX4 IHC was considered positive when strong nuclear expression was detected in more than 50% of neoplastic cells. When used as a surrogate for the diagnosis of CRS, the sensitivity and specificity of DUX4 IHC was 98 and 100%, respectively. Only one CRS case was negative for DUX4 IHC and harboured a CIC::FOXO4 fusion. CONCLUSIONS: DUX4 IHC is a highly sensitive and specific surrogate marker for the presence of CIC::DUX4 fusion, demonstrating its utility in establishing a diagnosis of CRS.

Biopticka laborator Ltd Pilsen Czech Republic

Department of Pathology and Laboratory Medicine Diagnostic Institute Cleveland Clinic Cleveland OH USA

Department of Pathology Charles University Faculty of Medicine in Pilsen Pilsen Czech Republic

Zobrazit více v PubMed

Bridge JA, editor. Chapter 3: undifferentiated small round cell sarcomas of bone and soft tissue. In WHO Classification of Tumours Editorial Board . Soft tissue and bone tumours. 5th ed.; Vol. 3. Lyon, France: International Agency for Research on Cancer, 2020. https://publications.iarc.fr/588 Accessed May 24, 2024

Kawamura‐Saito M, Yamazaki Y, Kaneko K et al. Fusion between CIC and DUX4 up‐regulates PEA3 family genes in Ewing‐like sarcomas with t(4;19)(q35;q13) translocation. Hum. Mol. Genet. 2006; 15; 2125–2137. PubMed

Antonescu CR, Owosho AA, Zhang L et al. Sarcomas with CIC‐rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am. J. Surg. Pathol. 2017; 41; 941–949. PubMed PMC

Simón‐Carrasco L, Jiménez G, Barbacid M, Drosten M. The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle 2018; 17; 702–711. PubMed PMC

Italiano A, Sung YS, Zhang L et al. High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1‐negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 2012; 51; 207–218. PubMed PMC

Choi EYK, Thomas DG, McHugh JB et al. Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC‐DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology. Am. J. Surg. Pathol. 2013; 37; 1379–1386. PubMed

Specht K, Sung Y, Zhang L, Richter GHS, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC‐DUX4 fusion–positive round cell tumors compared to EWSR1 ‐rearranged ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 2014; 53; 622–633. PubMed PMC

Ehrlich M, Jackson K, Tsumagari K, Camaño P, Lemmers RJFL. Hybridization analysis of D4Z4 repeat arrays linked to FSHD. Chromosoma 2007; 116; 107–116. PubMed PMC

Sparber‐Sauer M, Corradini N, Affinita MC et al. Clinical characteristics and outcomes for children, adolescents and young adults with “CIC‐fused” or “BCOR‐rearranged” soft tissue sarcomas: a multi‐institutional European retrospective analysis. Cancer Med. 2023; 12; 14346–14359. PubMed PMC

Palmerini E, Gambarotti M, Italiano A et al. A global collaboRAtive study of CIC‐rearranged, BCOR::CCNB3‐rearranged and other ultra‐rare unclassified undifferentiated small round cell sarcomas (GRACefUl). Eur. J. Cancer 2023; 183; 11–23. PubMed

Le Guellec S, Velasco V, Pérot G, Watson S, Tirode F, Coindre JM. ETV4 is a useful marker for the diagnosis of CIC‐rearranged undifferentiated round‐cell sarcomas: a study of 127 cases including mimicking lesions. Mod. Pathol. 2016; 29; 1523–1531. PubMed

Hung YP, Fletcher CD, Hornick JL. Evaluation of ETV4 and WT1 expression in CIC‐rearranged sarcomas and histologic mimics. Mod. Pathol. 2016; 29; 1324–1334. PubMed

Kao Y, Sung Y, Chen C et al. ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements. Genes Chromosomes Cancer 2017; 56; 501–510. PubMed PMC

Yoshida A, Arai Y, Kobayashi E et al. cic break‐apart fluorescence in‐situ hybridization misses a subset of cic – dux 4 sarcomas: a clinicopathological and molecular study. Histopathology 2017; 71; 461–469. PubMed

Smith SC, Buehler D, Choi EYK et al. CIC‐DUX sarcomas demonstrate frequent MYC amplification and ETS‐family transcription factor expression. Mod. Pathol. 2015; 28; 57–68. PubMed

Brčić I, Brodowicz T, Cerroni L et al. Undifferentiated round cell sarcomas with CIC‐DUX4 gene fusion: expanding the clinical spectrum. Pathology 2020; 52; 236–242. PubMed

Smith SC, Palanisamy N, Martin E et al. The utility of etv 1, etv 4 and etv 5 rna in‐situ hybridization in the diagnosis of cic – dux sarcomas. Histopathology 2017; 70; 657–663. PubMed

Siegele B, Roberts J, Black JO, Rudzinski E, Vargas SO, Galambos C. DUX4 immunohistochemistry is a highly sensitive and specific marker for CIC‐DUX4 fusion‐positive round cell tumor. Am. J. Surg. Pathol. 2017; 41; 423–429. PubMed

Snider L, Geng LN, Lemmers RJLF et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 2010; 6; e1001181. PubMed PMC

Klubíčková N, Dermawan JK, Mosaieby E et al. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with ntrk and other kinase gene aberrations. J. Pathol. 2024; 263; 61–73. PubMed

Dermawan JK, Cheng YW, Tu ZJ et al. Diagnostic utility of a custom 34‐gene anchored multiplex PCR‐based next‐generation sequencing fusion panel for the diagnosis of bone and soft tissue neoplasms with identification of novel USP6 fusion partners in aneurysmal bone cysts. Arch. Pathol. Lab Med. 2021; 145; 851–863. PubMed

Šteiner P, Andreasen S, Grossmann P et al. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands. Virchows Arch. 2018; 473; 471–480. PubMed

Black MA, Charville GW. Diagnosis of soft tissue tumors using immunohistochemistry as a surrogate for recurrent fusion oncoproteins. Semin. Diagn. Pathol. 2022; 39; 38–47. PubMed PMC

Anderson WJ, Hornick JL. Immunohistochemical correlates of recurrent genetic alterations in sarcomas. Genes Chromosomes Cancer 2019; 58; 111–123. PubMed

Baranov E, McBride MJ, Bellizzi AM et al. A novel SS18‐SSX fusion‐specific antibody for the diagnosis of synovial sarcoma. Am. J. Surg. Pathol. 2020; 44; 922–933. PubMed PMC

Sugita S, Arai Y, Aoyama T et al. NUTM2A‐CIC fusion small round cell sarcoma: a genetically distinct variant of CIC‐rearranged sarcoma. Hum. Pathol. 2017; 65; 225–230. PubMed

Sugita S, Arai Y, Tonooka A et al. A novel CIC‐FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing‐like sarcoma. Am. J. Surg. Pathol. 2014; 38; 1571–1576. PubMed

Le Loarer F, Pissaloux D, Watson S et al. Clinicopathologic features of CIC‐NUTM1 sarcomas, a new molecular variant of the family of CIC‐fused sarcomas. Am. J. Surg. Pathol. 2019; 43; 268–276. PubMed

Huang SC, Zhang L, Sung YS et al. Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations. Am. J. Surg. Pathol. 2016; 40; 645–655. PubMed PMC

Kojima N, Arai Y, Satomi K et al. Co‐expression of ERG and CD31 in a subset of CIC‐rearranged sarcoma: a potential diagnostic pitfall. Mod. Pathol. 2022; 35; 1439–1448. PubMed

Siegele BJ, Stemmer‐Rachamimov AO, Lilljebjorn H et al. N‐terminus dux4 ‐immunohistochemistry is a reliable methodology for the diagnosis of DUX4 ‐ fused B‐lymphoblastic leukemia/lymphoma (N‐terminus dux4 ihc for dux4 ‐fused b‐all). Genes Chromosomes Cancer 2022; 61; 449–458. PubMed

Ko JS, Marusic Z, Azzato EM et al. Superficial sarcomas with cic rearrangement are aggressive neoplasms: a series of eight cases. J. Cutan. Pathol. 2020; 47; 509–516. PubMed

Linos K, Dermawan JK, Bale T et al. Expanding the molecular diversity of CIC‐rearranged sarcomas with novel and very rare partners. Mod. Pathol. 2023; 36; 100103. PubMed PMC

Mancarella C, Carrabotta M, Toracchio L, Scotlandi K. CIC‐rearranged sarcomas: an intriguing entity that may lead the way to the comprehension of more common cancers. Cancer 2022; 14; 5411. PubMed PMC

Kim JW, Ponce RK, Okimoto RA. Capicua in human cancer. Trends Cancer 2021; 7; 77–86. PubMed PMC

Tanaka M, Yoshimoto T, Nakamura T. A double‐edged sword: the world according to Capicua in cancer. Cancer Sci. 2017; 108; 2319–2325. PubMed PMC

Yoshimoto T, Tanaka M, Homme M et al. CIC‐DUX4 induces small round cell sarcomas distinct from Ewing sarcoma. Cancer Res. 2017; 77; 2927–2937. PubMed PMC